Browse by People

Collapse authors list.
Rizzato, C, Campa, D, Talar-Wojnarowska, R, Halloran, C ORCID: 0000-0002-5471-4178, Kupcinskas, J, Butturini, G, Mohelníková-Duchoňová, B, Sperti, C, Tjaden, C, Ghaneh, P et al (show 19 more authors) , Hackert, T, Funel, N, Giese, N, Tavano, F, Pezzilli, R, Pedata, M, Pasquali, C, Gazouli, M, Mambrini, A, Souček, P, di Sebastiano, P, Capurso, G, Cantore, M, Oliverius, M, Offringa, R, Małecka-Panas, E, Strobel, O, Scarpa, A and Canzian, F (2016) Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis, 37 (10). pp. 957-964.

Collapse authors list.
Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J et al (show 24 more authors) , Darby, S, Meyer, T, Gillmore, R, Anthoney, A, Lind, P, Glimelius, B, Falk, S, Izbicki, JR, Middleton, GW, Cummins, S, Ross, PJ, Wasan, H, McDonald, A, Crosby, T, Ma, YT, Patel, K, Sherriff, D, Soomal, R, Borg, D, Sothi, S, Hammel, P, Hackert, T, Jackson, R and Büchler, MW (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet (London, England), 389 (10073). 1011 - 1024.

Collapse authors list.
Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J et al (show 24 more authors) , Darby, S, Meyer, T, Gillmore, R, Anthoney, A, Lind, P, Glimelius, B, Falk, S, Izbicki, JR, Middleton, GW, Cummins, S, Ross, PJ, Wasan, H, McDonald, A, Crosby, T, Ma, YT, Patel, K, Sherriff, D, Soomal, R, Borg, D, Sothi, S, Hammel, P, Hackert, T, Jackson, R and Büchler, MW (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet (London, England), 389 (10073). pp. 1011-1024.

Collapse authors list.
Botla, SK, Savant, S, Jandaghi, P, Bauer, AS, Mucke, O, Moskalev, EA, Neoptolemos, JP, Costello, E, Greenhalf, W, Scarpa, A et al (show 7 more authors) , Gaida, MM, Buchler, MW, Strobel, O, Hackert, T, Giese, NA, Augustin, HG and Hoheisel, JD (2016) Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression. Cancer Research, 76 (14). pp. 4149-4159.

Collapse authors list.
Jandaghi, P, Najafabadi, HS, Bauer, AS, Papadakis, AI, Fassan, M, Hall, A, Monast, A, Doeberitz, MVK, Neoptolemos, JP, Costello, E et al (show 15 more authors) , Greenhalf, W, Scarpa, A, Sipos, B, Auld, D, Lathrop, M, Park, M, Buechler, MW, Strobel, O, Hackert, T, Giese, NA, Zogopoulos, G, Sangwan, V, Huang, S, Riazalhosseini, Y and Hoheisel, JD (2016) Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Gastroenterology, 151 (6). pp. 1218-1231.

Collapse authors list.
Campa, D, Pastore, M, Gentiluomo, M, Talar-Wojnarowska, R, Kupcinskas, J, Malecka-Panas, E, Neoptolemos, JP, Niesen, W, Vodicka, P, Delle Fave, G et al (show 51 more authors) , Bueno-de-Mesquita, HB, Gazouli, M, Pacetti, P, Di Leo, M, Ito, H, Klueter, H, Soucek, P, Corbo, V, Yamao, K, Hosono, S, Kaaks, R, Vashist, Y, Gioffreda, D, Strobel, O, Shimizu, Y, Dijk, F, Andriulli, A, Ivanauskas, A, Bugert, P, Tavano, F, Vodickova, L, Zambon, CF, Lovecek, M, Landi, S, Key, TJ, Boggi, U, Pezzilli, R, Jamroziak, K, Mohelnikova-Duchonova, B, Mambrini, A, Bambi, F, Busch, O, Pazienza, V, Valente, R, Theodoropoulos, GE, Hackert, T, Capurso, G, Cavestro, GM, Pasquali, C, Basso, D, Sperti, C, Matsuo, K, Buechler, M, Khaw, K-T, Izbicki, J, Costello, E, Katzke, V, Michalski, C, Stepien, A, Rizzato, C and Canzian, F (2016) Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. ONCOTARGET, 7 (35). pp. 57011-57020.